Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $62.00 price target on the stock.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.